Format

Send to

Choose Destination
Hormones (Athens). 2017 Apr;16(2):181-193. doi: 10.14310/horm.2002.1732.

Bioimpedance analysis vs. DEXA as a screening tool for osteosarcopenia in lean, overweight and obese Caucasian postmenopausal females.

Author information

1
Endocrine and Metabolic Bone Disorders Unit, 2nd Department of Internal Medicine and Research Institute and Diabetes Center, Attikon University Hospital, Athens, Greece.
2
First Department of Pediatrics and Choremeion Research Laboratory, National and Kapodistrian University of Athens, Thivon & Levadeias Str., Goudi, Athens, 11527, Greece. cstefanaki@gmail.com.
3
Unit of Translational and Clinical Research in Endocrinology, Medical School, National and Kapodistrian University of Athens, Athens, Greece. cstefanaki@gmail.com.
4
BIOTEKNA Biomedical Technologies, Venice, Italy.
5
First Department of Pediatrics and Choremeion Research Laboratory, National and Kapodistrian University of Athens, Thivon & Levadeias Str., Goudi, Athens, 11527, Greece.
6
Unit of Translational and Clinical Research in Endocrinology, Medical School, National and Kapodistrian University of Athens, Athens, Greece.

Abstract

BACKGROUND-OBJECTIVES:

We aimed at evaluating the efficiency of a newly developed, advanced Bioimpedance Analysis (BIA-ACC®) device as a screening tool for determining the degree of obesity and osteosarcopenia in postmenopausal women with normal or decreased bone density determined by Dual-Energy X-Ray absorptiometry (DEXA) in a representative sample of Greek postmenopausal women.

METHODS:

This is a single-gate cross-sectional study of body composition measured by BIA-ACC® and DEXA. Postmenopausal females with BMI ranging from 18.5 to 40 kg/m2 were subjected to two consecutive measurements of DEXA and BIA-ACC® within 5-10 minutes of each other. We used Pearson's co-efficient to examine linear correlations, the intraclass correlation co-efficient (ICC) to test reliability, Bland-Atman plots to assess bias and Deming regressions to establish the agreement in parameters measured by BIA-ACC® and DEXA. Last, we used ANOVA, with Bonferroni correction and Dunnett T3 post hoc tests, for assessing the differences between quantitative and Pearson's x2 between qualitative variables.

SAMPLE AND RESULTS:

Our sample consisted of 84 overweight/obese postmenopausal women, aged 39-83 years, of whom 22 had normal bone density, 38 had osteopenia and 24 had osteoporosis based on DEXA measurements, using quota sampling. ICCs and Deming regressions showed strong agreement between BIA-ACC® and DEXA and demonstrated minimal proportional differences of no apparent clinical significance. Bland-Altman plots indicated minimal biases. Fat, skeletal and bone mass measured by BIA-ACC® and DEXA were increased in the non-osteopenic/non-osteoporotic women compared with those of the osteopenic and osteoporotic groups.

CONCLUSIONS:

BIA-ACC® is a rapid, bloodless and useful screening tool for determining body composition adiposity and presence of osteo-sarcopenic features in postmenopausal women. Women with osteopenia and osteoporosis evaluated by DEXA had decreased fat, skeletal and bone mass compared with normal bone density women, suggesting concordance in the change of these three organ masses in postmenopausal women.

PMID:
28742506
DOI:
10.14310/horm.2002.1732
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Springer Icon for Hormones
Loading ...
Support Center